UPDATE: TALAPRO-3, New Analysis Explores Talazoparib Benefit Across HRR Gene Mutations

New exploratory biomarker findings from the phase 3 TALAPRO-3 trial, provide further insight into how patients with different DNA repair gene alterations respond to the combination of talazoparib and enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC).

TALAPRO-3 previously demonstrated a significant improvement in radiographic progression-free survival (rPFS) with the addition of the PARP inhibitor talazoparib to enzalutamide in patients carrying homologous recombination repair (HRR) gene alterations.

The new analysis examined PSA progression across individual HRR gene subgroups and assessed whether achieving a very low PSA level within the first six months of treatment was associated with better clinical outcomes.

Across the overall study population, talazoparib plus enzalutamide reduced the risk of PSA progression by 49% compared with placebo plus enzalutamide.

The magnitude of the observed benefit varied across individual genetic subgroups:

• BRCA2: HR 0.45, corresponding to a 55% relative reduction in the hazard of PSA progression.
• CDK12: HR 0.42, corresponding to a 58% reduction.
• ATM: HR 0.61, suggesting a 39% reduction.
• CHEK2: HR 0.49, suggesting a 51% reduction.
• ATR: HR 0.25, suggesting a 75% reduction.

However, only the BRCA2 and CDK12 subgroups reached nominal statistical significance. Results for ATM, ATR, CHEK2, and other genes remained uncertain, mainly because of limited patient numbers and progression events. These exploratory comparisons were not designed to establish definitive differences in treatment efficacy between individual genetic alterations.

The ATM findings deserve particular attention. Although the numerical results favored the addition of talazoparib, the confidence interval crossed 1, meaning that a meaningful clinical benefit in this subgroup cannot yet be confirmed.

This distinction is biologically relevant because not all HRR gene alterations produce the same degree of sensitivity to PARP inhibition. Unlike BRCA2, ATM alterations do not necessarily result in the functional homologous recombination deficiency typically associated with greater PARP inhibitor sensitivity.

Another important finding concerned early PSA suppression. Patients who achieved PSA below 0.2 ng/mL after six months generally experienced better subsequent outcomes.

In the talazoparib plus enzalutamide arm, reaching this threshold was associated with a 63% lower hazard of radiographic progression or death (HR 0.37) and an 81% lower hazard of PSA progression (HR 0.19). Similar prognostic associations were observed in the control arm, reinforcing the value of early, deep PSA responses as indicators of subsequent disease control.

Source.